Centessa Positive Interim Phase 1 in Narcolepsy Study

 

• 2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT)
• Favorable safety and tolerability profile with no observations of frequently reported on-target adverse events (AEs) associated with other OX2R agonists, visual disturbances or hepatotoxicity as of the data cutoff date 1
• PK profile supports once-daily dosing
• Company plans to rapidly initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH)

https://www.globenewswire.com/news-release/2024/09/10/2943494/0/en/Centessa-Announces-Positive-Interim-Phase-1-Clinical-Data-with-its-Novel-Orexin-Receptor-2-OX2R-Agonist-ORX750-in-Acutely-Sleep-Deprived-Healthy-Volunteers.html